Hepatitis E Vaccines MarketSize, Share & Industry Analysis, 2026-2034By Vaccine Type / Platform TechnologyBy Development & Regulatory StageBy Genotype Coverage / Antigen TargetBy Dosing RegimenBy Target Population / Risk GroupBy Application / Use SettingBy Distribution / Procurement ChannelBy Adjuvant SystemBy End UserBy Route of Administration
Full title & scope — all 10 axes with their segments
Hepatitis E Vaccines Market Size, Share & Industry Analysis, By Vaccine Type / Platform Technology (Recombinant Protein / Virus-Like Particle (VLP) Vaccines, DNA-Based Vaccine Candidates, mRNA-Based Vaccine Candidates, Live-Attenuated Vaccine Candidates, Inactivated Whole-Virus Vaccine Candidates), By Development & Regulatory Stage (Licensed / Commercially Marketed, Phase III Clinical Trials, Phase II Clinical Trials, Phase I Clinical Trials, Preclinical Research Stage), By Genotype Coverage / Antigen Target (Genotype 1-Derived Antigen Candidates, Genotype 2-Relevant Candidates, Genotype 3-Relevant Candidates, Genotype 4-Relevant Candidates, Pan-Genotype (Cross-Protective) Candidates), By Dosing Regimen (Two-Dose Regimen (0, 1 Month), Three-Dose Regimen (0, 1, 6 Months), Single-Dose Candidates), By Target Population / Risk Group (Women of Reproductive Age, Including Pregnant Women, Children and Adolescents, General Adult Population in Endemic Areas, Travelers to Endemic Regions, Immunocompromised and Chronic Liver Disease Patients, Military and Occupational-Risk Personnel), By Application / Use Setting (Routine National Immunization Programs, Outbreak and Emergency Response Campaigns, Travel Medicine / Pre-Travel Vaccination, Occupational and Institutional Vaccination (Military, Healthcare Workers), Clinical Research and Trial Use), By Distribution / Procurement Channel (Government and National Immunization Programs, International and Multilateral Procurement (Gavi-Supported Stockpile, UNICEF Supply Division, ICG-Coordinated Emergency Stockpile), Private Hospitals and Clinics, Travel Medicine and Specialty Vaccination Clinics, Humanitarian and NGO-Led Outbreak Response Procurement), By Adjuvant System (Aluminum Hydroxide (Alum)-Adjuvanted, Non-Adjuvanted / Antigen-Only Formulations, Novel / Next-Generation Adjuvant Systems), By End User (Hospitals and Clinics, Government and Public Health Immunization Bodies, Travel Medicine and Occupational Health Clinics, Humanitarian and Outbreak-Response Organizations, Academic and Research Institutes), By Route of Administration (Intramuscular Injection, Investigational Needle-Free / Alternative Delivery Candidates), and Regional Forecast, 2026-2034
Talk to the analyst who built the estimates, and shape the scope around your question.
- 01By Vaccine Type / Platform TechnologyRecombinant Protein / Virus-Like Particle · DNA-Based Vaccine Candidates · mRNA-Based Vaccine Candidates
- 02By Development & Regulatory StageLicensed / Commercially Marketed · Phase III Clinical Trials · Phase II Clinical Trials
- 03By Genotype Coverage / Antigen TargetGenotype 1-Derived Antigen Candidates · Genotype 2-Relevant Candidates · Genotype 3-Relevant Candidates
- 04By Dosing RegimenTwo-Dose Regimen · 1 Month) · Three-Dose Regimen
- 05By Target Population / Risk GroupWomen of Reproductive Age · Including Pregnant Women · Children and Adolescents
- 06By Application / Use SettingRoutine National Immunization Programs · Outbreak and Emergency Response Campaigns · Travel Medicine / Pre-Travel Vaccination
- 07By Distribution / Procurement ChannelGovernment and National Immunization Programs · International and Multilateral Procurement · UNICEF Supply Division
- 08By Adjuvant SystemAluminum Hydroxide · Non-Adjuvanted / Antigen-Only Formulations · Novel / Next-Generation Adjuvant Systems
- 09By End UserHospitals and Clinics · Government and Public Health Immunization Bodies · Travel Medicine and Occupational Health Clinics
- 10By Route of AdministrationIntramuscular Injection · Investigational Needle-Free / Alternative Delivery Candidates
- 11By Region
Market Analysis & Outlook
Hepatitis E vaccines are prophylactic biologics developed to prevent infection with the hepatitis E virus, a pathogen transmitted primarily through contaminated water that causes acute liver disease and carries an elevated mortality risk during pregnancy. The category spans a single vaccine already licensed and administered in one national market alongside a pipeline of recombinant, DNA-based, mRNA-based, live-attenuated and inactivated candidates still in clinical development. Buyers include national immunization programs in endemic countries, international procurement bodies coordinating outbreak-response stockpiles, private hospitals and travel medicine clinics, and research institutes running clinical trials.
Between 2025 and 2034 the global hepatitis e vaccines market moves from USD 45.6 million to USD 247.5 million, compounding at 20.62% a year. Fifteen years are covered in all, taking in USD 18.2 million in 2020, USD 38.1 million in 2024, USD 55.2 million in 2026 and USD 117.6 million in 2030.
On the vaccine type / platform technology axis, growth rates run from 15.23% for Recombinant Protein / Virus-Like Particle (VLP) Vaccines up to 44.57% for mRNA-Based Vaccine Candidates. Recombinant Protein / Virus-Like Particle (VLP) Vaccines carries the volume: USD 41.27 million and 90.5% of revenue in 2025, USD 150.98 million and 61% in 2034. The lines gaining share are DNA-Based Vaccine Candidates, mRNA-Based Vaccine Candidates, Live-Attenuated Vaccine Candidates and Inactivated Whole-Virus Vaccine Candidates. Recombinant Protein / Virus-Like Particle (VLP) Vaccines lose share without losing revenue.
By development & regulatory stage, Licensed / Commercially Marketed accounts for 91% of 2025 revenue at USD 41.5 million, reaching USD 183.15 million and 74% by 2034. Phase III Clinical Trials grows faster at 36.37% against 17.93%, moving from 4% of revenue to 12% by 2034. This axis divides the same revenue as the vaccine type / platform technology split instead of adding to it, so the two are read together and never summed.
The regional order runs from Asia Pacific at 78% of 2025 revenue down to Latin America at 2%. Asia Pacific is worth USD 35.57 million in 2025 and USD 153.45 million in 2034; Middle East and Africa, second at 12%, moves from USD 5.47 million to USD 59.4 million. Middle East and Africa, Europe, North America and Latin America gain share across the period, so growth is not distributed evenly between regions.
Behind these figures sit five regions, five vaccine type / platform technology lines and ten segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.
Market Size, 2020–2034
USD MillionRevenue in USD Million. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global hepatitis e vaccines market moves from USD 18.2 million in 2020 to USD 45.6 million in 2025 and USD 247.5 million by 2034, the forecast period compounding at 20.62% a year.
- 90.5% of 2025 revenue sits in Recombinant Protein / Virus-Like Particle (VLP) Vaccines (USD 41.27 million) and it remains the largest vaccine type / platform technology line in 2034 at USD 150.98 million and 61%.
- Fastest growth on the vaccine type / platform technology axis belongs to mRNA-Based Vaccine Candidates: 44.57% a year, USD 1.14 million to USD 35.89 million, and a share moving from 2.5% to 14.5%.
- Against a base case of USD 247.5 million in 2034, the study also reports a bear case at USD 227.7 million and a bull case at USD 267.3 million, with the assumptions behind each set out separately.
- 78% of 2025 revenue is generated in Asia Pacific, worth USD 35.57 million and rising to USD 153.45 million by 2034; Latin America is smallest at 2%.
- Within Asia Pacific, China is the worked country example, at USD 24.9 million in 2025; 70% of regional revenue in the base year, and USD 99.74 million by 2034.
- Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.
Market Trends
Revenue Share, By Vaccine Type / Platform Technology
Base year 2025Recombinant Protein / Virus-Like Particle (VLP) Vaccines leads with 90.5% of vaccine type / platform technology segment revenue.
Share of vaccine type / platform technology segment revenue, most recent base year.
Three things move over 2026-2034, and they are worth separating: the vaccine type / platform technology mix, the regional balance, and the 20.62% compounding underneath both.
None of them reverses the market's direction. Every line and every region grows in absolute terms across the period; the movement is in which of them captures the revenue added.
Composition shifts on the vaccine type / platform technology axis. mRNA-Based Vaccine Candidates grows at 44.57% across 2026-2034 against 15.23% for Recombinant Protein / Virus-Like Particle (VLP) Vaccines, the widest spread on the vaccine type / platform technology axis. Shares follow: 2.5% to 14.5% for mRNA-Based Vaccine Candidates, 90.5% to 61% for Recombinant Protein / Virus-Like Particle (VLP) Vaccines. The revenue figures behind that are USD 1.14 million to USD 35.89 million and USD 41.27 million to USD 150.98 million. Both expand; where a supplier sits on the axis still decides whether it tracks the market.
Middle East and Africa, Europe, North America and Latin America gain regional share. Middle East and Africa moves from 12% of revenue in 2025 to 24% in 2034, worth USD 5.47 million rising to USD 59.4 million; Europe moves from 5% of revenue in 2025 to 7% in 2034, worth USD 2.28 million rising to USD 17.33 million; North America moves from 3% of revenue in 2025 to 4% in 2034, worth USD 1.37 million rising to USD 9.9 million; Latin America moves from 2% of revenue in 2025 to 3% in 2034, worth USD 0.91 million rising to USD 7.43 million. The offsetting side is Asia Pacific at 78% moving to 62%, none of which contracts. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.
The series never breaks trajectory. The market moves through USD 18.2 million in 2020, USD 38.1 million in 2024, USD 45.6 million in 2025, USD 55.2 million in 2026, USD 117.6 million in 2030 and USD 247.5 million in 2034. Against 20.17% through the historical period, the 20.62% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the vaccine type / platform technology and regional axes, not by the headline rate.
Market Growth Factors
mRNA-Based Vaccine Candidates adds the most incremental growth
Market Drivers
3- 01mRNA-Based Vaccine Candidates adds the most incremental growth
44.57% growth in mRNA-Based Vaccine Candidates, against 20.62% for the market as a whole, moves it from USD 1.14 million and 2.5% of revenue in 2025 to USD 35.89 million and 14.5% in 2034. The market's overall 20.62% depends on that rate holding: at the 15.23% recorded by Recombinant Protein / Virus-Like Particle (VLP) Vaccines, the same revenue base would compound to a materially smaller 2034 total. That makes position on the vaccine type / platform technology axis a growth decision, not a product one.
- 02Asia Pacific carries 78% of the base and keeps growing
78% of 2025 revenue (USD 35.57 million) is generated in Asia Pacific, reaching USD 153.45 million by 2034 at an unchanged 62%. Middle East and Africa adds a further 12% at USD 5.47 million, reaching USD 59.4 million. Most of the base and most of the growth sit in those two, and a plan spread evenly across regions therefore over-invests outside them.
- 03Fifteen years of unbroken growth underpin the forecast
The historical period compounded at 20.17%; USD 18.2 million in 2020, USD 38.1 million in 2024 and USD 45.6 million in 2025. From there the forecast carries 20.62% through to USD 247.5 million in 2034. Fifteen years of unbroken growth in the series means the forecast rests on a demonstrated trajectory, not a projected turnaround, and it is why the 20.62% rate is applied flat across the whole period instead of ramped through it.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Million) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Licensure and national program adoption spreading beyond the first market | High | +78 | Medium | High | High |
| 2 | Multilateral stockpile funding for outbreak-response vaccination campaigns | High | +52 | High | High | Medium |
| 3 | Pan-genotype and simplified-dosing candidates advancing through late-stage trials | Medium-High | +34 | Low | Medium | High |
| 4 | Prioritization of maternal mortality risk in immunization policy | Medium | +22 | Medium | Medium | Medium |
| 5 | Growth in travel medicine and occupational vaccination demand | Medium | +14 | Low | Medium | Medium |
| 6 | Others | Low | +21.9 | Low | Low | Low |
| Total | +221.9 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Million) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Manufacturing capacity concentrated among a small number of suppliers | Medium | −9 | High | Medium | Low |
| 2 | Absence of WHO prequalification limiting broader multilateral procurement | Medium | −7 | High | Medium | Low |
| 3 | Cost and cold-chain constraints in low-resource outbreak settings | Low | −4 | Medium | Medium | Low |
| Total | −20 | |||||
Drivers contribute 221.9 USD Million and restraints remove 20 USD Million, a net 201.9 USD Million, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Growth in the global hepatitis e vaccines market comes from three measurable sources over 2026-2034: the market's own compounding at 20.62%, the share gained by faster-growing vaccine type / platform technology lines, and expansion in the regions taking a larger part of global revenue.
Restraining Factors
The bear case and what drives it
Market Restraints
2- 01The bear case and what drives it
Bear case assumes multilateral stockpile funding is renewed on a reduced scale and no additional country reaches routine program listing within the forecast window, holding growth to the outbreak-response channel alone. On that assumption 2034 revenue lands at USD 227.7 million against the USD 247.5 million base case, from the same USD 45.6 million 2025 starting point.
- 02The largest line is not the fastest
With 90.5% of 2025 revenue (USD 41.27 million) Recombinant Protein / Virus-Like Particle (VLP) Vaccines is where most of the market sits, and it grows at only 15.23% against the market's 20.62%. Revenue still reaches USD 150.98 million by 2034 and share still falls to 61%: a drag on the average, not a decline.
Market Opportunities
Where the forecast could be beaten
Market Opportunities
2- 01Where the forecast could be beaten
What would beat the forecast: bull case assumes at least one additional country completes licensure and lists the vaccine in its routine national immunization program within the forecast window, pulling program-channel volume forward faster than the base case. That case reaches USD 267.3 million in 2034 against USD 247.5 million, and it is worth testing against a reader's own read of the market.
- 02The opening is on the vaccine type / platform technology axis, not the regional one
mRNA-Based Vaccine Candidates grows at 44.57% against 20.62% for the market, adding revenue from USD 1.14 million in 2025 to USD 35.89 million in 2034 and taking its share from 2.5% to 14.5%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Recombinant Protein / Virus-Like Particle (VLP) Vaccines.
Market Challenges
One vaccine type / platform technology line carries the market
Market Challenges
2- 01One vaccine type / platform technology line carries the market
One line dominates: Recombinant Protein / Virus-Like Particle (VLP) Vaccines, at 90.5% of revenue in 2025 and 61% in 2034, worth USD 41.27 million and USD 150.98 million. That concentration means the market's own forecast is, to a large extent, a forecast for one vaccine type / platform technology line.
- 02China is 70% of Asia Pacific
Of Asia Pacific's USD 35.57 million in 2025, USD 24.9 million (70%) comes from China alone, rising to USD 99.74 million by 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it, which a reader treating the region as diversified would miss.
Segmentation Analysis
10 axesThe market is divided by vaccine type / platform technology and by development & regulatory stage, genotype coverage / antigen target, dosing regimen, target population / risk group, application / use setting, distribution / procurement channel, adjuvant system, end user and route of administration; ten axes in all. Each axis cuts the same total revenue along a different commercial dimension, so the splits are alternative views of one market, not additions to it.
There are five lines on the vaccine type / platform technology axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: four gain it, the other gives it up.
By Vaccine Type / Platform Technology · 5 segments
By Vaccine Type / Platform Technology
- Largest Recombinant Protein / Virus-Like Particle (VLP) Vaccines · 90.5%
- Fastest mRNA-Based Vaccine Candidates · 44.6%
- Moves most Recombinant Protein / Virus-Like Particle (VLP) Vaccines · -29.5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Recombinant Protein / Virus-Like Particle (VLP) Vaccines | $41.27M | 90.5% | $151M | 61%-29.5 | 15.2% |
| DNA-Based Vaccine Candidates | $0.78M | 1.7% | $16.58M | 6.7%+5 | 39.5% |
| mRNA-Based Vaccine Candidates | $1.14M | 2.5% | $35.89M | 14.5%+12 | 44.6% |
| Live-Attenuated Vaccine Candidates | $1.37M | 3% | $18.56M | 7.5%+4.5 | 32.7% |
| Inactivated Whole-Virus Vaccine Candidates | $1.05M | 2.3% | $25.49M | 10.3%+8 | 40.7% |
Scale in Recombinant Protein / Virus-Like Particle (VLP) Vaccines and Growth in mRNA-Based Vaccine Candidates Define the Vaccine type / platform technology Axis Recombinant protein and virus-like particle platforms lead because the only vaccine with full regulatory licensure and years of real-world administration uses this technology, giving it manufacturing history and buyer confidence that unlicensed platforms lack. mRNA-based candidates grow fastest because sponsors are redirecting infrastructure and expertise built for other indications toward hepatitis E, shortening the path from trial to limited investigational supply. By 2034 Recombinant Protein / Virus-Like Particle (VLP) Vaccines is still ahead, making this a shift in weight, not a change of leader. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Development & Regulatory Stage · 5 segments
By Development & Regulatory Stage
- Largest Licensed / Commercially Marketed · 91%
- Fastest Phase III Clinical Trials · 36.4%
- Moves most Licensed / Commercially Marketed · -17 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Licensed / Commercially Marketed | $41.50M | 91% | $183M | 74%-17 | 17.9% |
| Phase III Clinical Trials | $1.82M | 4% | $29.70M | 12%+8 | 36.4% |
| Phase II Clinical Trials | $1.14M | 2.5% | $17.33M | 7%+4.5 | 35.3% |
| Phase I Clinical Trials | $0.68M | 1.5% | $9.90M | 4%+2.5 | 34.6% |
| Preclinical Research Stage | $0.46M | 1% | $7.43M | 3%+2 | 36.2% |
Scale in Licensed / Commercially Marketed and Growth in Phase III Clinical Trials Define the Development & regulatory stage Axis Licensed and commercially marketed vaccines lead because they are the only category generating recurring purchase revenue; everything still in trials earns from limited investigational supply agreements rather than routine procurement. Phase III programs grow fastest as several candidates approach regulatory filing and begin securing early-access and named-patient sales ahead of full licensure. By 2034 Licensed / Commercially Marketed is still ahead, making this a shift in weight, not a change of leader.
By Genotype Coverage / Antigen Target · 5 segments
Pan-Genotype (Cross-Protective) Candidates Outpaces the Axis While Genotype 1-Derived Antigen Candidates Holds the Largest Share
- Largest Genotype 1-Derived Antigen Candidates · 42%
- Fastest Pan-Genotype (Cross-Protective) Candidates · 37.3%
- Moves most Pan-Genotype (Cross-Protective) Candidates · +22 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Genotype 1-Derived Antigen Candidates | $19.15M | 42% | $74.25M | 30%-12 | 16.3% |
| Genotype 4-Relevant Candidates | $13.68M | 30% | $54.45M | 22%-8 | 16.6% |
| Genotype 3-Relevant Candidates | $4.56M | 10% | $22.28M | 9%-1 | 19.3% |
| Genotype 2-Relevant Candidates | $3.65M | 8% | $17.33M | 7%-1 | 18.9% |
| Pan-Genotype (Cross-Protective) Candidates | $4.56M | 10% | $79.20M | 32%+22 | 37.3% |
Genotype 1 and genotype 4 candidates lead because these are the strains most represented in the outbreak and endemic settings where procurement is currently concentrated, and the licensed vaccine's own clinical record was built against them. Pan-genotype candidates grow fastest as developers and procurement bodies favor cross-protective designs that avoid committing a national program to a single circulating strain. Leadership changes hands: Pan-Genotype (Cross-Protective) Candidates is the largest line by 2034, not Genotype 1-Derived Antigen Candidates.
By Dosing Regimen · 3 segments
Single-Dose Candidates (Investigational) Outpaces the Axis While Three-Dose Regimen (0, 1, 6 Months) Holds the Largest Share
- Largest Three-Dose Regimen (0, 1, 6 Months) · 82%
- Fastest Single-Dose Candidates (Investigational) · 39.1%
- Moves most Three-Dose Regimen (0, 1, 6 Months) · -24 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Three-Dose Regimen (0, 1, 6 Months) | $37.39M | 82% | $144M | 58%-24 | 16.1% |
| Two-Dose Regimen (0, 1 Month) | $5.93M | 13% | $59.40M | 24%+11 | 29.2% |
| Single-Dose Candidates (Investigational) | $2.28M | 5% | $44.55M | 18%+13 | 39.1% |
Three-dose regimens lead because the only licensed vaccine uses this schedule and national programs already have it built into their immunization calendars. Single-dose investigational candidates grow fastest because outbreak-response campaigns and travel medicine settings place a premium on completing protection in one visit, which eases delivery in the field settings where hepatitis E outbreaks concentrate. Three-Dose Regimen (0, 1, 6 Months) remains the largest line through 2034, so the axis changes in proportion, not in order.
By Target Population / Risk Group · 6 segments
By Target Population / Risk Group
- Largest Women of Reproductive Age, Including Pregnant Women · 32%
- Fastest Immunocompromised and Chronic Liver Disease Patients · 23.7%
- Moves most General Adult Population in Endemic Areas · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Women of Reproductive Age, Including Pregnant Women | $14.59M | 32% | $74.25M | 30%-2 | 19.8% |
| General Adult Population in Endemic Areas | $12.77M | 28% | $59.40M | 24%-4 | 18.6% |
| Children and Adolescents | $6.38M | 14% | $37.13M | 15%+1 | 21.6% |
| Immunocompromised and Chronic Liver Disease Patients | $5.47M | 12% | $37.13M | 15%+3 | 23.7% |
| Travelers to Endemic Regions | $4.10M | 9% | $27.23M | 11%+2 | 23.4% |
| Military and Occupational-Risk Personnel | $2.28M | 5% | $12.38M | 5% | 20.7% |
Scale in Women of Reproductive Age, Including Pregnant Women and Growth in Immunocompromised and Chronic Liver Disease Patients Define the Target population / risk group Axis Women of reproductive age lead because hepatitis E carries a materially higher mortality risk in pregnancy, which is the clinical rationale every current immunization strategy is built around. Immunocompromised and chronic liver disease patients grow fastest as clinicians extend protection to groups whose underlying condition raises the consequences of infection well beyond the general population. The order does not change: Women of Reproductive Age, Including Pregnant Women is still largest in 2034, and what moves is how much it holds.
By Application / Use Setting · 5 segments
Travel Medicine / Pre-Travel Vaccination Outpaces the Axis While Routine National Immunization Programs Holds the Largest Share
- Largest Routine National Immunization Programs · 38%
- Fastest Travel Medicine / Pre-Travel Vaccination · 22.8%
- Moves most Outbreak and Emergency Response Campaigns · -7 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Routine National Immunization Programs | $17.33M | 38% | $109M | 44%+6 | 22.7% |
| Outbreak and Emergency Response Campaigns | $15.50M | 34% | $66.83M | 27%-7 | 17.6% |
| Travel Medicine / Pre-Travel Vaccination | $5.47M | 12% | $34.65M | 14%+2 | 22.8% |
| Occupational and Institutional Vaccination (Military, Healthcare Workers) | $4.10M | 9% | $22.28M | 9% | 20.7% |
| Clinical Research and Trial Use | $3.19M | 7% | $14.85M | 6%-1 | 18.6% |
Routine national immunization programs lead because a licensed vaccine's largest and steadiest buyer is a national schedule rather than any single response campaign, and that share grows further as more endemic countries adopt it into routine use. Outbreak and emergency response campaigns still account for a large share because acute epidemics in fragile settings remain the scenario where hepatitis E vaccination is most urgently needed today. Travel Medicine / Pre-Travel Vaccination outgrows every other line on this axis, narrowing the gap to Routine National Immunization Programs. The order does not change: Routine National Immunization Programs is still largest in 2034, and what moves is how much it holds.
By Distribution / Procurement Channel · 5 segments
Private Hospitals and Clinics Outpaces the Axis While Government and National Immunization Programs Holds the Largest Share
- Largest Government and National Immunization Programs · 40%
- Fastest Private Hospitals and Clinics · 22.5%
- Moves most International and Multilateral Procurement (Gavi-Supported Stockpile, UNICEF Supply Division, ICG-Coordinated Emergency Stockpile) · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Government and National Immunization Programs | $18.24M | 40% | $104M | 42%+2 | 21.3% |
| International and Multilateral Procurement (Gavi-Supported Stockpile, UNICEF Supply Division, ICG-Coordinated Emergency Stockpile) | $13.68M | 30% | $64.35M | 26%-4 | 18.8% |
| Private Hospitals and Clinics | $6.38M | 14% | $39.60M | 16%+2 | 22.5% |
| Travel Medicine and Specialty Vaccination Clinics | $4.10M | 9% | $24.75M | 10%+1 | 22.1% |
| Humanitarian and NGO-Led Outbreak Response Procurement | $3.19M | 7% | $14.85M | 6%-1 | 18.6% |
Government and national immunization programs lead because a licensed vaccine's durable revenue comes from standing procurement contracts rather than one-off purchases, and that channel grows further as more countries move from pilot introduction to routine budget lines. Private hospitals and clinics grow fastest as commercial availability widens beyond the countries currently served through public program and multilateral channels alone. The order does not change: Government and National Immunization Programs is still largest in 2034, and what moves is how much it holds.
By Adjuvant System · 3 segments
Aluminum Hydroxide (Alum)-Adjuvanted Held the Dominant Share of the Adjuvant system Segment in 2025
- Largest Aluminum Hydroxide (Alum)-Adjuvanted · 70%
- Fastest Novel / Next-Generation Adjuvant Systems (Investigational) · 35%
- Moves most Novel / Next-Generation Adjuvant Systems (Investigational) · +14 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Aluminum Hydroxide (Alum)-Adjuvanted | $31.92M | 70% | $144M | 58%-12 | 18.2% |
| Non-Adjuvanted / Antigen-Only Formulations | $10.03M | 22% | $49.50M | 20%-2 | 19.4% |
| Novel / Next-Generation Adjuvant Systems (Investigational) | $3.65M | 8% | $54.45M | 22%+14 | 35% |
Alum-adjuvanted formulations lead because aluminum hydroxide is the adjuvant with the longest global safety record and the lowest regulatory friction for a first-generation vaccine. Novel adjuvant systems grow fastest as developers pursue formulations that can lower the antigen dose or shorten the dosing schedule, both of which matter directly to field delivery cost. Aluminum Hydroxide (Alum)-Adjuvanted remains the largest line through 2034, so the axis changes in proportion, not in order.
By End User · 5 segments
Hospitals and Clinics Led by End user in 2025, with Travel Medicine and Occupational Health Clinics Growing Fastest
- Largest Hospitals and Clinics · 34%
- Fastest Travel Medicine and Occupational Health Clinics · 22.5%
- Moves most Hospitals and Clinics · +2 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Hospitals and Clinics | $15.50M | 34% | $89.10M | 36%+2 | 21.4% |
| Government and Public Health Immunization Bodies | $14.59M | 32% | $74.25M | 30%-2 | 19.8% |
| Travel Medicine and Occupational Health Clinics | $6.38M | 14% | $39.60M | 16%+2 | 22.5% |
| Humanitarian and Outbreak-Response Organizations | $5.93M | 13% | $29.70M | 12%-1 | 19.6% |
| Academic and Research Institutes | $3.19M | 7% | $14.85M | 6%-1 | 18.6% |
Hospitals and clinics lead because they are the point of administration for both routine program doses and private-pay doses alike, which no other end-user category spans. Travel medicine and occupational health clinics grow fastest as commercial availability extends into markets where the vaccine is bought ahead of travel or assigned occupational exposure rather than distributed through a public program. Hospitals and Clinics remains the largest line through 2034, so the axis changes in proportion, not in order.
By Route of Administration · 2 segments
Investigational Needle-Free / Alternative Delivery Candidates Outpaces the Axis While Intramuscular Injection (Standard) Holds the Largest Share
- Largest Intramuscular Injection (Standard) · 96%
- Fastest Investigational Needle-Free / Alternative Delivery Candidates · 36.4%
- Moves most Intramuscular Injection (Standard) · -8 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Intramuscular Injection (Standard) | $43.78M | 96% | $218M | 88%-8 | 19.5% |
| Investigational Needle-Free / Alternative Delivery Candidates | $1.82M | 4% | $29.70M | 12%+8 | 36.4% |
Intramuscular injection leads because it is the only route used by the licensed vaccine and the route every regulatory pathway to date has been built around. Needle-free and alternative delivery candidates grow fastest because they remove the cold-chain and trained-staff burden that limits vaccination in the rural and outbreak settings where hepatitis E risk concentrates. By 2034 Intramuscular Injection (Standard) is still ahead, making this a shift in weight, not a change of leader.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
Asia Pacific Market Analysis
The largest region covered, and the one giving up the most — 16 points of share move elsewhere by 2034, while revenue still grows 4.3×.
- Rank 1 of 5
- 2025 share 78%
- By 2034 62%
- Revenue $35.57M → $153M
78% of the global hepatitis e vaccines market sits in Asia Pacific in 2025, worth USD 35.57 million rising to USD 153.45 million in 2034. Among the five regions it ranks first by revenue in both years.
Its share moves to 62% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The vaccine type / platform technology mix reported at global level applies here, with Recombinant Protein / Virus-Like Particle (VLP) Vaccines the largest line at 90.5% of 2025 revenue and mRNA-Based Vaccine Candidates the fastest-growing at 44.57%. Asia Pacific is reported axis by axis and country by country in the full study.
China
Sets the pace for Asia Pacific at 70% of it, growing 4.0×.
- In region 1 of 3
- Of region 70%
- Of global 54.6%
- Revenue $24.90M → $99.74M
China is the largest market within Asia Pacific, generating USD 24.9 million in 2025 and projected to reach USD 99.74 million by 2034. Carrying 70% of the region in the base year, it sets Asia Pacific's direction instead of merely contributing to it. Regional revenue of USD 35.57 million in 2025 and USD 153.45 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
The vaccine type / platform technology pattern in China is the global one: 90.5% of 2025 revenue in Recombinant Protein / Virus-Like Particle (VLP) Vaccines, 61% by 2034, against 44.57% growth in mRNA-Based Vaccine Candidates taking it from 2.5% to 14.5%. Since 70% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-vaccine type / platform technology revenue for China appears on its own in the full report.
In China, hepatitis E vaccines fall under the oversight of the National Medical Products Administration, which classifies them as biological products subject to registration, batch release testing, and ongoing pharmacovigilance reporting. A supplier must demonstrate conformity with national pharmacopoeia standards covering purity, potency, and stability before a product reaches clinical use. China is notable for having its own domestically developed and approved hepatitis E vaccine, so the regulatory pathway here is comparatively mature, encompassing post-marketing surveillance obligations and manufacturing site inspections. Labelling must meet NMPA requirements for indication, dosing, and storage conditions specific to biological products.
In China the field is Xiamen Innovax Biotech Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Ltd., Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd. (Sinopharm), GSK plc, Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Biological E. Limited, Panacea Biotec Ltd., Indian Immunologicals Ltd., PT Bio Farma (Persero), Company for Vaccine and Biological Production No.1 (VABIOTECH), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., National Vaccine and Serum Institute (Egypt), Institut Pasteur de Dakar, The Biovac Institute, Croda International plc and InvivoGen. Two different problems sit on the same axis: holding Recombinant Protein / Virus-Like Particle (VLP) Vaccines at 90.5% of 2025 revenue, and taking mRNA-Based Vaccine Candidates while it grows at 44.57%. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.
India
2nd-largest in Asia Pacific, growing 4.7×.
- In region 2 of 3
- Of region 20%
- Of global 15.6%
- Revenue $7.11M → $33.76M
15.6% of global revenue is generated in India; USD 7.11 million in 2025, reaching USD 33.76 million in 2034, and 20% of Asia Pacific.
Indonesia
3rd-largest in Asia Pacific, growing 5.0×.
- In region 3 of 3
- Of region 6%
- Of global 4.7%
- Revenue $2.13M → $10.74M
Indonesia is sized at USD 2.13 million in 2025, rising to USD 10.74 million by 2034; 4.7% of global revenue and 6% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 2nd-largest region covered — it picks up 12 points of share by 2034, while revenue still grows 10.9×.
- Rank 2 of 5
- 2025 share 12%
- By 2034 24%
- Revenue $5.47M → $59.40M
12% of the global hepatitis e vaccines market sits in Middle East and Africa in 2025, worth USD 5.47 million with USD 59.4 million projected for 2034. It is a mid-sized region on this axis, second by revenue throughout the period.
24% of global revenue sits here by 2034, up from the 2025 level, so the region grows faster than the market's 20.62% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.
The vaccine type / platform technology mix reported at global level applies here, with Recombinant Protein / Virus-Like Particle (VLP) Vaccines the largest line at 90.5% of 2025 revenue and mRNA-Based Vaccine Candidates the fastest-growing at 44.57%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.
South Sudan
The largest market in Middle East and Africa, growing 8.5×.
- In region 1 of 3
- Of region 45%
- Of global 5.4%
- Revenue $2.46M → $20.79M
South Sudan is the largest market within Middle East and Africa, generating USD 2.46 million in 2025 and projected to reach USD 20.79 million by 2034. At 45% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. Regional revenue of USD 5.47 million in 2025 and USD 59.4 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Composition here matches the global split: the largest line is Recombinant Protein / Virus-Like Particle (VLP) Vaccines at 90.5% of 2025 revenue, easing to 61% by 2034, and the fastest is mRNA-Based Vaccine Candidates at 44.57%, from 2.5% to 14.5%. With 45% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. South Sudan carries its own vaccine type / platform technology breakdown in the full report.
South Sudan does not operate a fully established national authority capable of independently evaluating and approving vaccine products. Oversight leans heavily on guidance from the World Health Organization and on regulatory decisions taken in other jurisdictions before a vaccine reaches the country. The Ministry of Health, through its drug and food authority function, oversees importation and distribution, typically channelling supply through international procurement mechanisms such as UNICEF or Gavi instead of a domestic approval process. A supplier entering this market generally needs WHO prequalification status and must meet cold chain and labelling standards recognised internationally, since local capacity for independent technical review remains limited.
In South Sudan the field is Xiamen Innovax Biotech Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Ltd., Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd. (Sinopharm), GSK plc, Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Biological E. Limited, Panacea Biotec Ltd., Indian Immunologicals Ltd., PT Bio Farma (Persero), Company for Vaccine and Biological Production No.1 (VABIOTECH), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., National Vaccine and Serum Institute (Egypt), Institut Pasteur de Dakar, The Biovac Institute, Croda International plc and InvivoGen. Recombinant Protein / Virus-Like Particle (VLP) Vaccines, at 90.5% of 2025 revenue, is where the volume sits, and mRNA-Based Vaccine Candidates, growing at 44.57%, is where position changes hands over the forecast period. The commercial size of that position is USD 5.47 million in 2025 and USD 59.4 million by 2034, 12% of the global total in the base year.
Chad
2nd-largest in Middle East and Africa, growing 9.5×.
- In region 2 of 3
- Of region 25%
- Of global 3%
- Revenue $1.37M → $13.07M
3% of global revenue is generated in Chad; USD 1.37 million in 2025, reaching USD 13.07 million in 2034, and 25% of Middle East and Africa.
Sudan
3rd-largest in Middle East and Africa, growing 10.9×.
- In region 3 of 3
- Of region 15%
- Of global 1.8%
- Revenue $0.82M → $8.91M
Sudan is sized at USD 0.82 million in 2025, rising to USD 8.91 million by 2034; 1.8% of global revenue and 15% of Middle East and Africa. It is reported separately from South Sudan across every segmentation axis in the full report.
Europe Market Analysis
The 3rd-largest region covered — it picks up 2 points of share by 2034, while revenue still grows 7.6×.
- Rank 3 of 5
- 2025 share 5%
- By 2034 7%
- Revenue $2.28M → $17.33M
Europe holds 5% of the global hepatitis e vaccines market in 2025, worth USD 2.28 million on the way to USD 17.33 million by 2034. It is a marginal region on this axis, third by revenue throughout the period.
Share climbs to 7% by 2034, on growth above the market's own 20.62%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Segment composition follows the global pattern: Recombinant Protein / Virus-Like Particle (VLP) Vaccines largest at 90.5% of 2025 revenue, mRNA-Based Vaccine Candidates fastest at 44.57%. Per-axis and per-country detail for Europe sits in the full report.
United Kingdom
The largest market in Europe, growing 7.6×.
- In region 1 of 3
- Of region 40%
- Of global 2%
- Revenue $0.91M → $6.93M
USD 0.91 million of Europe's 2025 revenue is generated in the United Kingdom, the region's largest market, reaching USD 6.93 million by 2034. Its 40% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 2.28 million in 2025 and USD 17.33 million in 2034, it is the country the full report breaks out in detail.
Composition here matches the global split: the largest line is Recombinant Protein / Virus-Like Particle (VLP) Vaccines at 90.5% of 2025 revenue, easing to 61% by 2034, and the fastest is mRNA-Based Vaccine Candidates at 44.57%, from 2.5% to 14.5%. With 40% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-vaccine type / platform technology revenue for the United Kingdom appears on its own in the full report.
The United Kingdom regulates hepatitis E vaccines through the Medicines and Healthcare products Regulatory Agency, which classifies them as biological medicines requiring a marketing authorisation before supply. A manufacturer must submit evidence of quality, safety, and efficacy, and each batch is subject to independent release testing coordinated with the National Institute for Biological Standards and Control. Labelling and product information must follow MHRA conventions for biological products, covering storage, handling, and adverse reaction reporting through the Yellow Card scheme. Manufacturing sites are inspected against Good Manufacturing Practice standards, and any change to formulation or process typically requires a variation to the existing authorisation.
Xiamen Innovax Biotech Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Ltd., Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd. (Sinopharm), GSK plc, Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Biological E. Limited, Panacea Biotec Ltd., Indian Immunologicals Ltd., PT Bio Farma (Persero), Company for Vaccine and Biological Production No.1 (VABIOTECH), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., National Vaccine and Serum Institute (Egypt), Institut Pasteur de Dakar, The Biovac Institute, Croda International plc and InvivoGen are the suppliers covered in the United Kingdom. Volume sits in Recombinant Protein / Virus-Like Particle (VLP) Vaccines at 90.5% of 2025 revenue; movement sits in mRNA-Based Vaccine Candidates at 44.57% growth. A supplier weighted toward Europe is competing over a base of USD 2.28 million in 2025, reaching USD 17.33 million by 2034 on the trajectory this study models.
Germany
2nd-largest in Europe, growing 7.6×.
- In region 2 of 3
- Of region 35%
- Of global 1.8%
- Revenue $0.80M → $6.07M
1.75% of global revenue is generated in Germany; USD 0.8 million in 2025, reaching USD 6.07 million in 2034, and 35% of Europe.
Netherlands
3rd-largest in Europe, growing 7.6×.
- In region 3 of 3
- Of region 25%
- Of global 1.3%
- Revenue $0.57M → $4.33M
The Netherlands is sized at USD 0.57 million in 2025, rising to USD 4.33 million by 2034; 1.25% of global revenue and 25% of Europe. It is reported separately from the United Kingdom across every segmentation axis in the full report.
North America Market Analysis
The 4th-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 7.2×.
- Rank 4 of 5
- 2025 share 3%
- By 2034 4%
- Revenue $1.37M → $9.90M
North America holds 3% of the global hepatitis e vaccines market in 2025, worth USD 1.37 million rising to USD 9.9 million in 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.
By 2034 the share has moved up to 4%, on growth above the market's own 20.62%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Recombinant Protein / Virus-Like Particle (VLP) Vaccines leads here as it does globally, at 90.5% of 2025 revenue, and mRNA-Based Vaccine Candidates again grows fastest at 44.57%. Per-axis and per-country detail for North America sits in the full report.
United States
Sets the pace for North America at 84.7% of it, growing 7.3×.
- In region 1 of 2
- Of region 84.7%
- Of global 2.5%
- Revenue $1.16M → $8.42M
USD 1.16 million of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 8.42 million by 2034. At 84.7% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 1.37 million in 2025 and USD 9.9 million in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.
Demand in the United States follows the vaccine type / platform technology mix reported at global level: Recombinant Protein / Virus-Like Particle (VLP) Vaccines is the largest line at 90.5% of 2025 revenue, moving to 61% by 2034, while mRNA-Based Vaccine Candidates grows fastest at 44.57% and takes its share from 2.5% to 14.5%. Because the country carries 84.7% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-vaccine type / platform technology revenue for the United States appears on its own in the full report.
In the United States, hepatitis E vaccines would fall under the Food and Drug Administration, specifically its Center for Biologics Evaluation and Research, which governs vaccines through the Biologics License Application pathway distinct from the drug approval route used for small-molecule medicines. A sponsor must demonstrate manufacturing consistency, clinical safety, and efficacy, and each lot is subject to release testing before distribution. Labelling must meet FDA requirements for prescribing information and storage conditions, and post-marketing safety is tracked through the Vaccine Adverse Event Reporting System. Facilities are inspected under current Good Manufacturing Practice standards, and any licensed product remains subject to ongoing pharmacovigilance obligations.
Xiamen Innovax Biotech Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Ltd., Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd. (Sinopharm), GSK plc, Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Biological E. Limited, Panacea Biotec Ltd., Indian Immunologicals Ltd., PT Bio Farma (Persero), Company for Vaccine and Biological Production No.1 (VABIOTECH), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., National Vaccine and Serum Institute (Egypt), Institut Pasteur de Dakar, The Biovac Institute, Croda International plc and InvivoGen are the suppliers covered in the United States. The commercially relevant division is 90.5% of 2025 revenue in Recombinant Protein / Virus-Like Particle (VLP) Vaccines, where the volume is, against 44.57% growth in mRNA-Based Vaccine Candidates, where share moves. A supplier weighted toward North America is competing over a base of USD 1.37 million in 2025 reaching USD 9.9 million by 2034, 3% of global revenue at the start of that period.
Canada
2nd-largest in North America, growing 7.1×.
- In region 2 of 2
- Of region 15.3%
- Of global 0.5%
- Revenue $0.21M → $1.49M
Canada is sized at USD 0.21 million in 2025, rising to USD 1.49 million by 2034; 0.46% of global revenue and 15.3% of North America. It is reported separately from the United States across every segmentation axis in the full report.
Latin America Market Analysis
The 5th-largest region covered — it picks up 1 point of share by 2034, while revenue still grows 8.2×.
- Rank 5 of 5
- 2025 share 2%
- By 2034 3%
- Revenue $0.91M → $7.43M
USD 0.91 million of 2025 revenue is generated in Latin America, 2% of the global hepatitis e vaccines market rising to USD 7.43 million in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.
Share climbs to 3% by 2034, on growth above the market's own 20.62%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
Within the region the vaccine type / platform technology split tracks the global one; 90.5% of 2025 revenue in Recombinant Protein / Virus-Like Particle (VLP) Vaccines, fastest growth of 44.57% in mRNA-Based Vaccine Candidates. Per-axis and per-country detail for Latin America sits in the full report.
Brazil
Sets the pace for Latin America at 60% of it, growing 8.1×.
- In region 1 of 2
- Of region 60%
- Of global 1.2%
- Revenue $0.55M → $4.46M
60% of Latin America's base-year revenue comes from Brazil; USD 0.55 million, rising to USD 4.46 million by 2034. Because it is 60% of the region in the base year, Latin America's totals move with this one country instead of a spread of them. Set against USD 0.91 million and USD 7.43 million for the region, it is why this market, and not a smaller one, is the one reported in full.
The vaccine type / platform technology pattern in Brazil is the global one: 90.5% of 2025 revenue in Recombinant Protein / Virus-Like Particle (VLP) Vaccines, 61% by 2034, against 44.57% growth in mRNA-Based Vaccine Candidates taking it from 2.5% to 14.5%. With 60% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-vaccine type / platform technology revenue for Brazil appears on its own in the full report.
Brazil regulates hepatitis E vaccines through the Agência Nacional de Vigilância Sanitária, which classifies them as biological products requiring formal registration before a supplier can market or distribute them domestically. An applicant must submit clinical and manufacturing data demonstrating safety, efficacy, and consistency across production batches, alongside proof of Good Manufacturing Practice conformity at each manufacturing site. Labelling must comply with ANVISA's requirements for biological medicines, including storage conditions, batch identification, and prescribing information in Portuguese. Any vaccine considered for inclusion in the national immunization program undergoes additional technical evaluation by the Ministry of Health, coordinated alongside the standard registration process.
In Brazil the field is Xiamen Innovax Biotech Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Ltd., Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd. (Sinopharm), GSK plc, Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Biological E. Limited, Panacea Biotec Ltd., Indian Immunologicals Ltd., PT Bio Farma (Persero), Company for Vaccine and Biological Production No.1 (VABIOTECH), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., National Vaccine and Serum Institute (Egypt), Institut Pasteur de Dakar, The Biovac Institute, Croda International plc and InvivoGen. Two different problems sit on the same axis: holding Recombinant Protein / Virus-Like Particle (VLP) Vaccines at 90.5% of 2025 revenue, and taking mRNA-Based Vaccine Candidates while it grows at 44.57%. A supplier weighted toward Latin America is competing over a base of USD 0.91 million in 2025, reaching USD 7.43 million by 2034 on the trajectory this study models.
Mexico
2nd-largest in Latin America, growing 8.3×.
- In region 2 of 2
- Of region 40%
- Of global 0.8%
- Revenue $0.36M → $2.97M
Mexico is sized at USD 0.36 million in 2025, rising to USD 2.97 million by 2034; 0.79% of global revenue and 40% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Vaccine Type / Platform Technology, Development & Regulatory Stage, Genotype Coverage / Antigen Target, Dosing Regimen, Target Population / Risk Group, Application / Use Setting, Distribution / Procurement Channel, Adjuvant System, End User, Route of Administration, and regional analysis covers Asia Pacific, Middle East and Africa, Europe, North America, Latin America, each broken out by country.
Competitive Landscape
Scale in Recombinant Protein / Virus-Like Particle (VLP) Vaccines and Growth in mRNA-Based Vaccine Candidates Set the Terms of Competition
The field covered here is Xiamen Innovax Biotech Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Ltd., Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd. (Sinopharm), GSK plc, Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Biological E. Limited, Panacea Biotec Ltd., Indian Immunologicals Ltd., PT Bio Farma (Persero), Company for Vaccine and Biological Production No.1 (VABIOTECH), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., National Vaccine and Serum Institute (Egypt), Institut Pasteur de Dakar, The Biovac Institute, Croda International plc and InvivoGen.
The vaccine type / platform technology axis, not the regional one, is where competition happens. The largest block of revenue is Recombinant Protein / Virus-Like Particle (VLP) Vaccines: USD 41.27 million in 2025 at 90.5% of the total, 61% in 2034. Incumbency there is expensive to challenge. Movement is concentrated in mRNA-Based Vaccine Candidates; 44.57% growth, against 15.23% at the other end of the axis in Recombinant Protein / Virus-Like Particle (VLP) Vaccines. Holding the first and taking the second are separate capabilities, which is why a market of USD 45.6 million supports as many suppliers as it does.
Hepatitis E vaccine supply is separated less by marketing scale than by regulatory and manufacturing track record: the manufacturer with an actually licensed product holds a multi-year head start in production experience and post-marketing safety data that no pipeline developer can match yet. Among the trial-stage entrants, the deciding capability is clinical and regulatory execution, moving a candidate through the trial phases and toward a filing, since none can yet compete on installed capacity or channel reach. Adjuvant and formulation suppliers compete on a different basis entirely: reliability of raw-material supply to the vaccine developers rather than on any vaccine sale of their own.
Presence matters unevenly by region. With 78% of 2025 revenue in Asia Pacific and 12% in Middle East and Africa, a supplier's coverage of those two decides most of its addressable base before any product question arises.
Company-level profiles, financials, shares and development histories are held in the full report and not in this summary.
List of Key Hepatitis E Vaccines Market Companies Profiled
22 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Xiamen Innovax Biotech Co., Ltd.(China)
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.(China)
- Zydus Lifesciences Ltd.(India)
- Changchun Institute of Biological Products Co., Ltd.(China)
- China National Biotec Group Co., Ltd. (Sinopharm)(China)
- GSK plc(United Kingdom)
- Serum Institute of India Pvt. Ltd.(India)
- Bharat Biotech International Ltd.(India)
- Biological E. Limited(India)
- Panacea Biotec Ltd.(India)
- Indian Immunologicals Ltd.(India)
- PT Bio Farma (Persero)(Indonesia)
- Company for Vaccine and Biological Production No.1 (VABIOTECH)(Vietnam)
- Walvax Biotechnology Co., Ltd.(China)
- Chengdu Institute of Biological Products Co., Ltd.(China)
- Wuhan Institute of Biological Products Co., Ltd.(China)
- Beijing Minhai Biotechnology Co., Ltd.(China)
- National Vaccine and Serum Institute (Egypt)(Egypt)
- Institut Pasteur de Dakar(Senegal)
- The Biovac Institute(South Africa)
- Croda International plc(United Kingdom)
- InvivoGen(United States)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 10 axes (Vaccine Type / Platform Technology, Development & Regulatory Stage, Genotype Coverage / Antigen Target, Dosing Regimen, Target Population / Risk Group, Application / Use Setting, Distribution / Procurement Channel, Adjuvant System, End User, Route of Administration), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 22 key companies, and the research methodology behind every estimate.
Segmentation
10 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Hepatitis E Vaccines Market Size & Projections, 2020–2034, Revenue (USD Million)
Chapter 16.Global Hepatitis E Vaccines Market Overview, By Vaccine Type / Platform Technology, 2020–2034, Revenue (USD Million)
Chapter 17.Global Hepatitis E Vaccines Market Overview, By Development & Regulatory Stage, 2020–2034, Revenue (USD Million)
Chapter 18.Global Hepatitis E Vaccines Market Overview, By Genotype Coverage / Antigen Target, 2020–2034, Revenue (USD Million)
Chapter 19.Global Hepatitis E Vaccines Market Overview, By Dosing Regimen, 2020–2034, Revenue (USD Million)
Chapter 20.Global Hepatitis E Vaccines Market Overview, By Target Population / Risk Group, 2020–2034, Revenue (USD Million)
Chapter 21.Global Hepatitis E Vaccines Market Overview, By Application / Use Setting, 2020–2034, Revenue (USD Million)
Chapter 22.Global Hepatitis E Vaccines Market Overview, By Distribution / Procurement Channel, 2020–2034, Revenue (USD Million)
Chapter 23.Global Hepatitis E Vaccines Market Overview, By Adjuvant System, 2020–2034, Revenue (USD Million)
Chapter 24.Global Hepatitis E Vaccines Market Overview, By End User, 2020–2034, Revenue (USD Million)
Chapter 25.Global Hepatitis E Vaccines Market Overview, By Route of Administration, 2020–2034, Revenue (USD Million)
Chapter 26.Global Hepatitis E Vaccines Market Size — Segment Comparison
Chapter 27.Global Hepatitis E Vaccines Geography Overview, 2020–2034, Revenue (USD Million)
Chapter 28.North America Hepatitis E Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 29.Europe Hepatitis E Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 30.Asia Pacific Hepatitis E Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 31.Latin America Hepatitis E Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 32.Middle East and Africa Hepatitis E Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Million)
Chapter 33.Application / Use-Case Analysis
Chapter 34.Vendor Capability Scorecard
Chapter 35.Scenario Forecasts
Chapter 36.Top 10 Key Clients of Top 10 Players
Chapter 37.Top 10 Suppliers
Chapter 38.Competitive Landscape
Chapter 39.Partnerships & M&A
Chapter 40.Key Vendor Analysis
Chapter 41.Marketing Strategy Analysis, Distributors & Traders
Chapter 42.Outlook of the Market
Chapter 43.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
10 axesBy Vaccine Type / Platform Technology
5- 01Recombinant Protein / Virus-Like Particle (VLP) Vaccines
- 02DNA-Based Vaccine Candidates
- 03mRNA-Based Vaccine Candidates
- 04Live-Attenuated Vaccine Candidates
- 05Inactivated Whole-Virus Vaccine Candidates
By Development & Regulatory Stage
5- 01Licensed / Commercially Marketed
- 02Phase III Clinical Trials
- 03Phase II Clinical Trials
- 04Phase I Clinical Trials
- 05Preclinical Research Stage
By Genotype Coverage / Antigen Target
5- 01Genotype 1-Derived Antigen Candidates
- 02Genotype 2-Relevant Candidates
- 03Genotype 3-Relevant Candidates
- 04Genotype 4-Relevant Candidates
- 05Pan-Genotype (Cross-Protective) Candidates
By Dosing Regimen
6- 01Two-Dose Regimen (0
- 021 Month)
- 03Three-Dose Regimen (0
- 041
- 056 Months)
- 06Single-Dose Candidates (Investigational)
By Target Population / Risk Group
7- 01Women of Reproductive Age
- 02Including Pregnant Women
- 03Children and Adolescents
- 04General Adult Population in Endemic Areas
- 05Travelers to Endemic Regions
- 06Immunocompromised and Chronic Liver Disease Patients
- 07Military and Occupational-Risk Personnel
By Application / Use Setting
6- 01Routine National Immunization Programs
- 02Outbreak and Emergency Response Campaigns
- 03Travel Medicine / Pre-Travel Vaccination
- 04Occupational and Institutional Vaccination (Military
- 05Healthcare Workers)
- 06Clinical Research and Trial Use
By Distribution / Procurement Channel
7- 01Government and National Immunization Programs
- 02International and Multilateral Procurement (Gavi-Supported Stockpile
- 03UNICEF Supply Division
- 04ICG-Coordinated Emergency Stockpile)
- 05Private Hospitals and Clinics
- 06Travel Medicine and Specialty Vaccination Clinics
- 07Humanitarian and NGO-Led Outbreak Response Procurement
By Adjuvant System
3- 01Aluminum Hydroxide (Alum)-Adjuvanted
- 02Non-Adjuvanted / Antigen-Only Formulations
- 03Novel / Next-Generation Adjuvant Systems (Investigational)
By End User
5- 01Hospitals and Clinics
- 02Government and Public Health Immunization Bodies
- 03Travel Medicine and Occupational Health Clinics
- 04Humanitarian and Outbreak-Response Organizations
- 05Academic and Research Institutes
By Route of Administration
2- 01Intramuscular Injection (Standard)
- 02Investigational Needle-Free / Alternative Delivery Candidates
Segment categories shown for scope reference. See the Summary tab for revenue share by Vaccine Type / Platform Technology. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The estimate is built upward from administered and procured doses rather than from top-down analogy. The base includes commercial doses sold in the one market where a hepatitis E vaccine carries full licensure, doses purchased through outbreak-response stockpile mechanisms coordinated by international procurement bodies, and investigational doses supplied under clinical trial and named-patient agreements for candidates still in development. Each volume is priced at the channel it actually clears through: public-program tender pricing, multilateral stockpile pricing and private commercial pricing are kept separate rather than averaged. The resulting total is checked against the disclosed revenue of the vaccine's manufacturer; where the two diverge, the dose or price assumption feeding the bottom-up build is corrected, not the other way round.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interview targets are drawn from the roles that actually decide a purchase or a program listing: immunization program managers and procurement officers at national health ministries, technical staff at the multilateral bodies that coordinate outbreak-response stockpiles, medical affairs and market access contacts at the vaccine's manufacturer and at the developers running late-stage candidates, and travel medicine clinicians who prescribe the vaccine commercially. Sampling weights the countries where hepatitis E is endemic or has run a recent outbreak response, together with the market where the vaccine is already licensed, over geographies where the disease burden or the regulatory pathway is not yet established.
Desk research draws on the WHO prequalification and position-paper documentation for hepatitis E vaccination, national immunization program registers in the countries where the licensed vaccine is listed, procurement and tender records published by the multilateral bodies that fund outbreak-response campaigns, clinical trial registries covering the recombinant, DNA-based, mRNA-based, live-attenuated and inactivated candidates in development, and the manufacturer's own disclosed shipment and revenue figures. Trade and customs classifications for vaccine shipments are used to cross-check reported volumes where a country's program data is incomplete.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from the pace at which additional endemic countries are expected to move from pilot introduction to routine program listing, the rate at which multilateral stockpile funding converts outbreak response into standing procurement, and the timing at which the pipeline candidates furthest along in development could reach licensure. Pricing is held broadly flat in real terms within each channel, since a materially lower price would need a second licensed entrant to force it. The forecast normalizes for the unevenness of outbreak-driven stockpile purchases in the historical years, smoothing single large campaign years rather than projecting them forward as a new baseline.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs are back-tested against the recorded year-on-year growth in the licensed vaccine's own disclosed shipment volumes over the historical period, and the segment-level shifts implied by the forecast, such as the rising share of multilateral and program-channel doses, are reviewed against how comparable single-manufacturer vaccine categories transitioned once a second channel opened. Sensitivities were run on the timing of pipeline candidates reaching licensure and on the pace of new country program adoption, since those two assumptions move the outer forecast years the most. The historical series was checked for internal consistency across the dose, price and revenue figures before being carried into the forecast build.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmer for the licensed vaccine's program-channel and stockpile-channel revenue, where dose volumes and public procurement pricing are directly observable. It is weaker for the pipeline candidates split by platform, genotype coverage and dosing regimen, where reported figures are triangulated from trial-supply agreements and adjacent vaccine categories rather than from disclosed commercial sales. A structural risk to the entire estimate is the small number of manufacturers currently active in this category. The entry, delay or exit of a single developer would move the forecast meaningfully more than in a category served by many competing suppliers.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Hepatitis E Vaccines Market projected to reach?
USD 247.5 USD Million by 2034, CAGR 20.62%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
Asia Pacific leads with 78% of global revenue through 2034.
05Which segment leads the market?
Recombinant Protein / Virus-Like Particle (VLP) Vaccines is the largest line by Vaccine Type / Platform Technology, at 90.5% of revenue in 2025.
06Who are the key companies profiled?
Xiamen Innovax Biotech Co., Ltd., Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Zydus Lifesciences Ltd., Changchun Institute of Biological Products Co., Ltd., China National Biotec Group Co., Ltd. (Sinopharm), GSK plc, Serum Institute of India Pvt. Ltd., Bharat Biotech International Ltd., Biological E. Limited, Panacea Biotec Ltd., Indian Immunologicals Ltd., PT Bio Farma (Persero), Company for Vaccine and Biological Production No.1 (VABIOTECH), Walvax Biotechnology Co., Ltd., Chengdu Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., National Vaccine and Serum Institute (Egypt), Institut Pasteur de Dakar, The Biovac Institute, Croda International plc, InvivoGen. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.